drugset / Trial / NCT03333057

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03333057

Phase 2 Completed 336 enrolled Novaliq GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).

Timeline

Start
2018-01-03
Primary completion
2018-05-18
Completion
2018-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Perfluorohexyloctane Unknown

Indications